Skip to content
DataLookout
Menu

Agni-01NCT06060613

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 18 versions: 18 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 10 → 14 locations
  2. Minor Enrollment increased: 208 → 254 participants
    • Eligibility criteria expanded, about 91 words
    • Study description expanded, about 10 words
    • Site details revised at 8 of 10 sites
  3. Minor Site details revised at 1 of 10 sitesv16
  4. Minor Study sites: 9 to 10v15
  5. Notable Primary and study completion pushed from Jun 30, 2028 to Jun 30, 2029
    • Site contacts updated at 2 of 9 sites
    • Eligibility criteria shortened, about 1 word
    v14
Show 12 earlier versionsHide 12 earlier versions
  1. Notable Enrollment target: 52 to 208v13 Show 4 more changesShow less
    • Primary endpoints: 2 to 3
    • Eligibility criteria expanded, about 269 words
    • Study description expanded, about 180 words
    • Site contacts updated at 1 of 9 sites
  2. Notable Primary and study completion dates pushed to Jun 30, 2028
    • Site contacts updated at 1 of 9 sites
    v12
  3. Minor Site contacts updated at 2 of 9 sitesv11
  4. Minor Study sites: 8 to 9
    • Eligibility criteria expanded, about 11 words
    v10
  5. Minor Study sites: 7 to 8v9
  6. Minor Site contacts updated at 1 of 7 sitesv8
  7. Minor Study sites: 6 to 7
    • Eligibility criteria expanded, about 45 words
    v7
  8. Minor Study sites: 4 to 6
    • Eligibility criteria expanded, about 19 words
    v6
  9. Minor Study sites: 2 to 4v5
  10. Notable Enrollment target: 32 to 52v4 Show 5 more changesShow less
    • Eligibility criteria expanded, about 67 words
    • Secondary endpoints: details revised at 1 of 2 entries
    • Study sites revised (2)
    • Study description shortened, about 2 words
    • Study title shortened, about 4 words
  11. Minor Site details revised at 1 of 2 sitesv3
  12. Notable Trial status: Active, Not Recruiting to Recruiting
    • Start date: Sep 22, 2023 to Oct 25, 2023
    • Site details revised at 2 of 2 sites
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence and nature of dose-limiting toxicities (DLTs)
Timeframe: 28 Days
The proportion of participants who have a confirmed complete response (CR) or partial response (PR) per RECIST v1.1
Timeframe: 2 years

Secondary (2)

The proportion of participants who have a confirmed CR or PR per RECIST v1.1
Incidence of AEs

Arms and interventions

Participants with advanced solid tumorsExperimental

Participants will receive conditioning therapy prior to administration of OBX-115 regimen.

Biologicals: OBX-115

Sites

14 sites in 2 countries

United States 13, Australia 1